...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group
【24h】

Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group

机译：米托蒽醌在转移性阑尾中的研究：EORTC胃肠道癌合作组的II期研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We performed a phase II study with mitoxantrone in patients with carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid. Thirty-five eligible patients received mitoxantrone 12 mg m-2 i.v. every 3 weeks. Among 18 previously untreated patients, three responded (17%, 95% CI = 4-41%); no responses were achieved in 17 previously treated patients. Of the 21 patients who had carcinoid tumours, 11 were previously untreated and two achieved a response (18%, 95% CI = 2-52%). Overall response rate was 9% (95% CI = 2-23%). At a median follow-up of 43 months, median overall survival was 16 months. The median survival of 21 patients with a normal alkaline phosphatase was 29 months and 9 months for 14 patients with elevated serum levels (P = 0.005). A similar observation was noticed for gamma-glutamyltransferase (P = 0.007). We concluded that mitoxantrone is not active in APUD tumours. Elevated alkaline phosphatase and gamma-glutamyltransferase are associated with a poor prognosis.
机译：我们对患有类癌，胰岛细胞瘤和甲状腺髓样癌的患者进行了米托蒽醌的II期研究。 35名合格患者接受米托蒽醌12 mg m-2 i.v.每3周一次。在18位先前未接受治疗的患者中，有3位有反应（17％，95％CI = 4-41％）; 17名先前接受过治疗的患者未获得任何反应。在21名患有类癌肿瘤的患者中，有11名以前未接受过治疗，其中2名获得了缓解（18％，95％CI = 2-52％）。总体缓解率为9％（95％CI = 2-23％）。在中位随访43个月时，中位总生存期为16个月。 21名碱性磷酸酶正常的患者的中位生存期为29个月，而14例血清水平升高的患者的中位生存期为9个月（P = 0.005）。对于γ-谷氨酰转移酶也观察到类似的观察结果（P ＝ 0.007）。我们得出的结论是，米托蒽醌在APUD肿瘤中不活跃。碱性磷酸酶和γ-谷氨酰转移酶升高与预后不良有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号